---
id: aan-antiseizure-pregnancy-2024
title: "Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: AAN/AES/SMFM Practice Guideline"
short_title: "AAN Antiseizure Meds Pregnancy 2024"

organization: American Academy of Neurology
collaborators:
  - American Epilepsy Society
  - Society for Maternal-Fetal Medicine
country: US
url: https://www.aan.com/Guidelines/home/GuidelineDetail/1240
doi: 10.1212/WNL.0000000000209279
pmid: 38748979
open_access: true

specialty: neurology
guideline_type: clinical-practice
evidence_system: other
conditions:
  - epilepsy in pregnancy
  - antiseizure medications
  - teratogenesis
tags:
  - pregnancy
  - folic acid
  - valproate
  - congenital malformations
  - neurodevelopmental outcomes

publication_date: 2024-05-15
previous_version_date: 2009-04-01
status: current
supersedes: aan-antiseizure-pregnancy-2009
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-21
---

## Scope

Evidence-based guidance on effects of antiseizure medications and folic acid supplementation on major congenital malformations, adverse perinatal outcomes, and neurodevelopmental outcomes in children born to people with epilepsy.

## Notes

Joint guideline with AES and SMFM. Updates 2009 guideline with substantial new evidence on newer antiseizure medications.
